185 related articles for article (PubMed ID: 15596215)
1. Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: a pilot study.
Rehman I; Azzouzi AR; Catto JW; Allen S; Cross SS; Feeley K; Meuth M; Hamdy FC
Urology; 2004 Dec; 64(6):1238-43. PubMed ID: 15596215
[TBL] [Abstract][Full Text] [Related]
2. High level of phosphatidylcholines/lysophosphatidylcholine ratio in urine is associated with prostate cancer.
Li X; Nakayama K; Goto T; Kimura H; Akamatsu S; Hayashi Y; Fujita K; Kobayashi T; Shimizu K; Nonomura N; Ogawa O; Inoue T
Cancer Sci; 2021 Oct; 112(10):4292-4302. PubMed ID: 34328656
[TBL] [Abstract][Full Text] [Related]
3. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
[TBL] [Abstract][Full Text] [Related]
4. Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer.
Ummanni R; Junker H; Zimmermann U; Venz S; Teller S; Giebel J; Scharf C; Woenckhaus C; Dombrowski F; Walther R
Cancer Lett; 2008 Aug; 266(2):171-85. PubMed ID: 18384941
[TBL] [Abstract][Full Text] [Related]
5. Protein profiling of post-prostatic massage urine specimens by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to discriminate between prostate cancer and benign lesions.
Okamoto A; Yamamoto H; Imai A; Hatakeyama S; Iwabuchi I; Yoneyama T; Hashimoto Y; Koie T; Kamimura N; Mori K; Yamaya K; Ohyama C
Oncol Rep; 2009 Jan; 21(1):73-9. PubMed ID: 19082445
[TBL] [Abstract][Full Text] [Related]
6. [Nuclear matrix proteins differentially expressed in human prostate cancer cell lines and benign prostatic hyperplasia epithelial cell line].
Sun TC; Xin L; Song LM; Zhou Y; Ning LF; Han LY; Guo Y; Yu HM; Wang HP
Zhonghua Nan Ke Xue; 2012 Jul; 18(7):583-9. PubMed ID: 22994041
[TBL] [Abstract][Full Text] [Related]
7. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of prostate cancer metastasis-derived prostasomes.
Ronquist KG; Ronquist G; Larsson A; Carlsson L
Anticancer Res; 2010 Feb; 30(2):285-90. PubMed ID: 20332430
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
[TBL] [Abstract][Full Text] [Related]
10. Differential profiling of prostate tumors versus benign prostatic tissues by using a 2DE-MALDI-TOF-based proteomic approach.
Kmeťová Sivoňová M; Tatarková Z; Jurečeková J; Kliment J; Híveš M; Lichardusová L; Kaplán P
Neoplasma; 2021 Jan; 68(1):154-164. PubMed ID: 32977723
[TBL] [Abstract][Full Text] [Related]
11. Stage-specific quantitative changes in renal and urinary proteome during the progression and development of streptozotocin-induced diabetic nephropathy in rats.
Sharma V; Tikoo K
Mol Cell Biochem; 2014 Mar; 388(1-2):95-111. PubMed ID: 24281856
[TBL] [Abstract][Full Text] [Related]
12. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
Li C; Zang T; Wrobel K; Huang JT; Nabi G
Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
[TBL] [Abstract][Full Text] [Related]
13. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine.
M'Koma AE; Blum DL; Norris JL; Koyama T; Billheimer D; Motley S; Ghiassi M; Ferdowsi N; Bhowmick I; Chang SS; Fowke JH; Caprioli RM; Bhowmick NA
Biochem Biophys Res Commun; 2007 Feb; 353(3):829-34. PubMed ID: 17194448
[TBL] [Abstract][Full Text] [Related]
14. MALDI MS profiling of post-DRE urine samples highlights the potential of β-microseminoprotein as a marker for prostatic diseases.
Flatley B; Wilmott KG; Malone P; Cramer R
Prostate; 2014 Jan; 74(1):103-11. PubMed ID: 24115268
[TBL] [Abstract][Full Text] [Related]
15. Furan and p-xylene as candidate biomarkers for prostate cancer.
Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
[TBL] [Abstract][Full Text] [Related]
16. In the search of novel urine biomarkers for the early diagnosis of prostate cancer. Intracellular or secreted proteins as the target group? Where and how to search for possible biomarkers useful in the everyday clinical practice.
Katafigioti A; Katafigiotis I; Sfoungaristos S; Alamanis C; Stravodimos K; Anastasiou I; Roumelioti E; Duvdevani M; Constantinides C
Arch Ital Urol Androl; 2016 Oct; 88(3):195-200. PubMed ID: 27711093
[TBL] [Abstract][Full Text] [Related]
17. Proteome analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Park SJ; Yoon WG; Song JS; Jung HS; Kim CJ; Oh SY; Yoon BH; Jung G; Kim HJ; Nirasawa T
Proteomics; 2006 Jan; 6(1):349-63. PubMed ID: 16294308
[TBL] [Abstract][Full Text] [Related]
18. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
Pang J; Liu WP; Liu XP; Li LY; Fang YQ; Sun QP; Liu SJ; Li MT; Su ZL; Gao X
J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
[TBL] [Abstract][Full Text] [Related]
19. Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer.
Yan C; Kim YH; Kang HW; Seo SP; Jeong P; Lee IS; Kim D; Kim JM; Choi YH; Moon SK; Yun SJ; Kim WJ
J Korean Med Sci; 2015 Dec; 30(12):1784-92. PubMed ID: 26713053
[TBL] [Abstract][Full Text] [Related]
20. The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage.
Meid FH; Gygi CM; Leisinger HJ; Bosman FT; Benhattar J
J Urol; 2001 May; 165(5):1802-5. PubMed ID: 11342979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
